# Chemed Corp: Form 10-Q for the period ended Jun 30, 2022

- Company: [Chemed Corp](/companies/che.md) (CIK 19584)
- Form: 10-Q
- Filed: 2022-07-29
- Accepted by EDGAR: Jul 29, 2022, 10:04 ET
- Period: 2022-06-30
- Accession: 0001562762-22-000308
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/19584/000156276222000308/che-20220630x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/19584/000156276222000308/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-04-01 to 2022-06-30 | $297.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2022-01-01 to 2022-06-30 | $597.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2022-04-01 to 2022-06-30 | $336.8m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2022-01-01 to 2022-06-30 | $673.4m | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months, 2022-04-01 to 2022-06-30 | $87.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2022-01-01 to 2022-06-30 | $177.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2022-04-01 to 2022-06-30 | $91.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2022-01-01 to 2022-06-30 | $181.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2022-04-01 to 2022-06-30 | $902.0k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2022-01-01 to 2022-06-30 | $1.7m | us-gaap:InterestExpense |
| Income tax | 3 months, 2022-04-01 to 2022-06-30 | $19.6m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2022-01-01 to 2022-06-30 | $40.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-04-01 to 2022-06-30 | $66.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2022-01-01 to 2022-06-30 | $130.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-04-01 to 2022-06-30 | $4.40 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2022-01-01 to 2022-06-30 | $8.62 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-04-01 to 2022-06-30 | $4.45 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2022-01-01 to 2022-06-30 | $8.73 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-04-01 to 2022-06-30 | 15,111,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2022-01-01 to 2022-06-30 | 15,152,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2022-01-01 to 2022-06-30 | $157.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2022-01-01 to 2022-06-30 | $25.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months, 2022-01-01 to 2022-06-30 | $10.7m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 6 months, 2022-01-01 to 2022-06-30 | $77.2m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2022-06-30 | $9.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-06-30 | $203.1m | us-gaap:AssetsCurrent |
| Total assets | at 2022-06-30 | $1.31bn | us-gaap:Assets |
| Current liabilities | at 2022-06-30 | $285.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-06-30 | $628.0m | us-gaap:Liabilities |
| Long-term debt | at 2022-06-30 | $111.8m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2022-06-30 | $5.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2022-06-30 | $685.0m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2022-06-30 | 14,904,946 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 51,457 characters.

### Executive Summary

We operate through our two wholly-owned subsidiaries, VITAS Healthcare Corporation and Roto-Rooter Group, Inc. VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible. Through its teams of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter’s services are focused on providing plumbing, drain cleaning, water restoration and other related services to both residential and commercial customers. Through its network of company-owned branches, Independent Contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.

The following is a summary of the key operating results (in thousands except per share amounts):

|  | Three months ended June 30, 2022 | 2021 | Six months ended June 30, 2022 | 2021 |
| --- | ---: | ---: | ---: | ---: |
| Service revenues and sales | **$531,288** | $532,256 | **$1,061,837** | $1,059,616 |
| Net income | **$66,456** | $56,522 | **$130,625** | $121,922 |
| Diluted EPS | **$4.40** | $3.51 | **$8.62** | $7.52 |
| Adjusted net income | **$73,090** | $74,100 | **$145,870** | $146,470 |
| Adjusted diluted EPS | **$4.84** | $4.60 | **$9.63** | $9.04 |
| Adjusted EBITDA | **$110,907** | $110,948 | **$221,114** | $219,467 |
| Adjusted EBITDA as a % of revenue | **20.9%** | 20.8% | **20.8%** | 20.7% |

Adjusted net income, adjusted diluted EPS, earnings before interest, taxes and depreciation and amortization (“EBITDA”), Adjusted EBITDA and Adjusted EBITDA as a percent of revenue are not measures derived in accordance with US GAAP. We provide non-GAAP measures to help readers evaluate our operating results and to compare our operating performance with that of similar companies that have different capital structures. Our non-GAAP measures should not be considered in isolation or as a substitute for comparable measures presented in accordance with GAAP. A reconciliation of our non-GAAP measures is presented on pages 34-36.

For the three months ended June 30, 2022, the decrease in consolidated service revenues and sales was driven by a 6.0% increase at Roto-Rooter offset by a 4.5% decrease at VITAS. The increase in service revenues at Roto-Rooter was driven by an increase in all major service lines. The decrease in service revenues at VITAS is comprised primarily of a 3.8% decrease in days-of-care offset by a geographically weighted average Medicare reimbursement rate increase of approximately 0.8%. Acuity mix shift had a net impact of reducing revenue approximately 1.6% in the quarter when compared to the prior year revenue and level-of-care mix. The combination of an increase in Medicare cap and other contra revenue changes positively impacted revenue growth by approximately 10 basis points. See page 37 for additional VITAS operating metrics.

For the six months ended June 30, 2022, the increase in consolidated service revenues and sales was driven by a 7.6% increase at Roto-Rooter offset by a 4.9% decrease at VITAS. The increase in service revenues at Roto-Rooter was driven by an increase in all major service lines. The decrease in service revenues at VITAS is comprised primarily of a 3.9% decrease in days-of-care offset by a geographically weighted average Medicare reimbursement rate increase of approximately 1.0%. Acuity mix shift had a net impact of reducing revenue approximately 1.9% over the six months when compared to the prior year revenue and level-of-care mix. The combination of an increase in Medicare cap and other contra revenue changes negatively impacted revenue growth by approximately 10 basis points. See page 37 for additional VITAS operating metrics.

We are closely monitoring the impact of the pandemic on all aspects of our business including impacts to employees, customers, patients, suppliers and vendors. The length and severity of the pandemic, coupled with related governmental actions including relief acts and actions relating to our workforce at federal, state and local levels, and underlying economic disruption will determine the ultimate short-term and long-term impact to our business operations and financial results. We are unable to predict the myriad of possible issues that could arise or the ultimate effect to our businesses as a result of the unknown short, medium and long-term impacts that the pandemic will have on the United States economy and society as a whole.

Historically, Chemed earnings guidance has been developed using previous periods’ key operating metrics which are then modeled and projected out for future periods. Critical within these projections is the understanding of traditional patterned correlations among key operating metrics. This modeling exercise also takes into consideration anticipated industry and macro-economic issues outside of management’s control but are somewhat predictable in terms of timing and impact on our business segments’ operating results.

The COVID-19 pandemic, uncertainty regarding forward looking inflation, and a potential economic recession, has made accurate modeling and providing meaningful earnings guidance exceptionally challenging. Since the start of the pandemic, Chemed has been able to successfully navigate within this rapidly changing environment and produce operating results that we believe provide us with the ability to issue earnings guidance for the remainder of the 2022 calendar year. However, this guidance should be taken with the recognition the above macro issues will continue to disrupt our healthcare system and general economy to such an extent that future rules, regulations and government mandates could materially impact the company’s ability to achieve this guidance.

Based upon the above discussion, VITAS 2022 revenue, prior to Medicare Cap, is estimated to decline 4.5% to 5.0% when compared to 2021. A portion of the estimated revenue reduction, approximately $15 million, is the result of the phase out of sequestration relief over the first half of 2022 compared to a full year of sequestration relief in 2021. ADC is estimated to decline 3.5%. Full year adjusted EBITDA margin, prior to Medicare Cap, is estimated to be 17.0% to 17.2%. We are currently estimating $10 million for Medicare Cap billing limitations in calendar year 2022.

Roto-Rooter is forecasted to achieve full-year 2022 revenue growth of 5.5% to 5.7%. Roto-Rooter’s adjusted EBITDA margin for 2022 is expected to be 29.2% to 29.5%.

Based upon the above, full-year 2022 earnings per diluted share, excluding non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items, is estimated to be in the range of $19.30 to $19.50. This 2022 guidance assumes an effective corporate tax rate on adjusted earnings of 25.1% and a diluted share count of 15.12 million shares. Chemed’s 2021 reported adjusted earnings per diluted share was $19.33.

On June 28, 2022, we replaced our existing credit facility with a fifth amended and restated Credit Agreement (“2022 Credit Facilities”). Terms of the 2022 Credit Facilities consist of a five-year $450 million revolver as well as a five-year $100 million term loan. Principal payments of $1.25 million on the term loan are due on the last day of each fiscal quarter, with a final payment due at the end of the agreement. The interest rate on the 2022 Credit Facilities has a floating rate that is generally SOFR plus an additional tiered rate which varies based on our current leverage ratio. As of June 30, 2022, the interest rate is SOFR plus 100 basis points. The 2022 Credit Facilities includes an expansion feature that provides the Company the opportunity to increase its revolver and or term loan by an additional $250 million.

We have issued $46.2 million in standby letters of credit as of June 30, 2022, mainly for insurance purposes. Issued letters of credit reduce our available credit under the 2022 Credit Facilities. As of June 30, 2022, we have approximately $387.0 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility. Management believes its liquidity and sources of capital are satisfactory for the Company’s needs in the foreseeable future.

We anticipate that our operating income and cash flows will be sufficient to operate our businesses and meet any commitments for the foreseeable future.

### Financial Condition

### Liquidity and Capital Resources

Material changes in the balance sheet accounts from December 31, 2021 to June 30, 2022 include the following:

A $5.0 million increase in the current portion of long-term debt due to the new term loan established with the 2022 Credit Facilities.

A $27.3 million decrease in accrued compensation due to the payment of 2021 bonuses in the first quarter of 2022.

A $73.2 million decrease in long-term debt due to repayments.

A $103.2 million increase in treasury stock due mainly to stock repurchases.

Net cash provided by operating activities increased $25.6 million from June 30, 2021 to June 30, 2022. The main drivers of the increase are an increase in net income of $8.7 million, coupled with changes in current assets and liabilities. Significant changes in our accounts receivable balances are typically driven by the timing of payments received from the Federal government at our VITAS subsidiary. We typically receive a payment in excess of $42.0 million from the Federal government for hospice services every other Friday. The timing of a period end will have a significant impact on the accounts receivable at VITAS. These changes generally normalize over a two year period, as cash flow variations in one year are offset in the following year.

Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.

### Commitments and Contingencies

Collectively, the terms of The 2022 Credit Facilities require us to meet various financial covenants, to be tested quarterly. We are in compliance with all financial and other debt covenants as of June 30, 2022 and anticipate remaining in compliance throughout the foreseeable future.

We are subject to various lawsuits and claims in the normal course of our business. In addition, we periodically receive communications from governmental and regulatory agencies concerning compliance with Medicare and Medicaid billing requirements at our VITAS subsidiary. We establish reserves for specific, uninsured liabilities in connection with regulatory and legal action that we deem to be probable and estimable. We disclose the existence of regulatory and legal actions when we believe it is reasonably possible that a loss could occur in connection with the specific action. In most instances, we are unable to make a reasonable estimate of any reasonably possible liability due to the uncertainty of the outcome and stage of litigation. We record legal fees associated with legal and regulatory actions as the costs are incurred.

See Note 10 in the Notes to the Unaudited Consolidated Financial Statements in Item 1 above for a description of current material legal matters.

### Results of Operations

### Three months ended June 30, 2022 versus 2021 - Consolidated Results

Our service revenues and sales for the second quarter of 2022 decreased 0.2% versus services and sales revenues for the second quarter of 2021. Of this decrease, a $13.2 million increase was attributable to Roto-Rooter, offset by a $14.2 million decrease attributable to VITAS. The following chart shows the components of revenue by operating segment (in thousands):

| VITAS | Three months ended June 30, 2022 | 2021 | Increase/(Decrease) Percent |
| --- | ---: | ---: | ---: |
| Routine homecare | **$257,631** | $264,926 | (2.8) |
| Continuous care | **19,538** | 24,282 | (19.5) |
| General inpatient | **24,619** | 27,371 | (10.1) |
| Other | **3,213** | 3,078 | 4.4 |
| Subtotal | **305,001** | 319,657 | (4.6) |
| Medicare cap adjustment | **(2,000)** | (2,000) | - |
| Room and board - net | **(2,166)** | (2,657) | 18.5 |
| Implicit price concessions | **(3,054)** | (3,065) | 0.4 |
| Net revenue | **$297,781** | $311,935 | (4.5) |
| Roto-Rooter |  |  |  |
| Drain cleaning | **$64,532** | $62,649 | 3.0 |
| Plumbing | **48,885** | 44,609 | 9.6 |
| Excavation | **55,546** | 55,114 | 0.8 |
| Other | **155** | 311 | (50.2) |
| Subtotal - short term core | **169,118** | 162,683 | 4.0 |
| Water restoration | **43,673** | 38,583 | 13.2 |
| Independent Contractors | **21,005** | 19,026 | 10.4 |
| Outside franchisee fees | **1,370** | 1,255 | 9.2 |
| Other | **4,240** | 3,882 | 9.2 |
| Gross revenue | **239,406** | 225,429 | 6.2 |
| Implicit price concessions | **(5,899)** | (5,108) | (15.5) |
| Net revenue | **233,507** | 220,321 | 6.0 |
| Total Revenues | $531,288 | $532,256 | (0.2) |

Days of care at VITAS during the quarter ended June 30 were as follows:

|  | Days of Care 2022 | 2021 | Increase/(Decrease) Percent |
| --- | ---: | ---: | ---: |
| Routine homecare | **1,266,604** | 1,335,482 | (5.2) |
| Nursing home | **259,046** | 244,423 | 6.0 |
| Respite | **6,095** | 5,338 | 14.2 |
| Subtotal routine homecare and respite | **1,531,745** | 1,585,243 | (3.4) |
| General inpatient | **23,155** | 26,493 | (12.6) |
| Continuous care | **20,802** | 25,786 | (19.3) |
| Total days of care | **1,575,702** | 1,637,522 | (3.8) |

The decrease in service revenues at VITAS is comprised primarily of a 3.8% decrease in days-of-care offset by a geographically weighted average Medicare reimbursement rate increase of approximately 0.8%. Acuity mix shift had a net impact of reducing revenue approximately 1.6% in the quarter when compared to the prior year revenue and level-of-care mix. The combination of an increase in Medicare cap and other contra revenue changes positively impacted revenue growth by approximately 10 basis points.

The increase in plumbing revenues for the second quarter of 2022 versus 2021 is attributable to a 12.5% increase in price and service mix shift offset by a 2.9% decrease in job count. Drain cleaning revenues for the second quarter of 2022 versus 2021 reflect an 10.7% increase in price and service mix shift offset by a 7.7% decrease in job count. Excavation and water restoration jobs are generally sold as a result of initial calls from customers regarding drain cleaning issues. As a result, the 0.8% increase in excavation revenue and the 13.2% increase in water restoration revenue are mainly a function of the numbers and size of drain cleaning issues we encounter on a quarterly basis. Independent Contractor revenue increased 10.4% due mainly to increased expansion into water restoration.

The consolidated gross margin was 36.6% in the second quarter of 2022 as compared with 34.1% in the second quarter of 2021. On a segment basis, VITAS’ gross margin was 23.6% in the second quarter of 2022 as compared with 20.7%, in the second quarter of 2021 primarily due to improved labor and ancillary costs. The Roto-Rooter segment’s gross margin was 53.2% for the second quarter of 2022 which is essentially equal to the second quarter of 2021.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

|  | Three months ended June 30, 2022 | 2021 |
| --- | ---: | ---: |
| SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts | **$91,422** | $88,510 |
| Impact of market value adjustments related to assets held in deferred compensation trusts | **(5,086)** | 3,655 |
| Long-term incentive compensation | **1,517** | 1,673 |
| Total SG&A expenses | **$87,853** | $93,838 |

SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts for the second quarter of 2022 were up 3.3% when compared to the second quarter of 2021. This increase was mainly a result of the increase in variable selling and general administrative expenses and due to normal salary increases.

Amortization for the second quarter of 2022 was flat when compared to the second quarter of 2021. Quarterly amortization of intangible assets is mainly driven by two Roto-Rooter franchise acquisitions completed in 2019. The total purchase price of these acquisitions was $138.0 million. As part of the purchase price allocation, approximately $59.2 million was determined to be the value of reacquired franchise rights which are being amortized over the remaining life of each franchise agreement. The average remaining life on the reacquired franchise agreements was approximately seven years. Quarterly amortization of reacquired franchise rights for these two acquisitions is approximately $2.0 million ($8.1 million annualized through 2026). This contrasts to quarterly franchise fees historically collected from these two franchisees of approximately $470,000 ($1.9 million annualized).

Other (expense)/income – net comprise (in thousands):

|  | Three months ended June 30, 2022 | 2021 |
| --- | ---: | ---: |
| Market value adjustment on assets held in deferred compensation trusts | **$(5,086)** | $3,655 |
| Interest income | **154** | 138 |
| Other | **2** | (8) |
| Total (expense)/other income - net | **$(4,930)** | $3,785 |

Our effective tax rate reconciliation is as follows (in thousands):

|  | Three months ended June 30, 2022 | 2021 |
| --- | ---: | ---: |
| Income tax provision calculated at the statutory federal rate | **$18,082** | $15,772 |
| Stock compensation tax benefits | **(2,499)** | (868) |
| State and local income taxes | **2,744** | 2,671 |
| Other--net | **1,323** | 1,008 |
| Income tax provision | **$19,650** | $18,583 |
| Effective tax rate | 22.8% | 24.7% |

Net income for both periods included the following after-tax items/adjustments that (reduced) or increased after-tax earnings (in thousands):

| VITAS | Three months ended June 30, 2022 | 2021 |
| --- | ---: | ---: |
| Medicare cap sequestration adjustment | **$(103)** | $- |
| Direct costs related to COVID-19 | **60** | (8,268) |
| Facility relocation costs | **-** | (1,384) |
| Roto-Rooter |  |  |
| Amortization of reacquired franchise agreements | **(1,729)** | (1,729) |
| Direct costs related to COVID-19 | **-** | (428) |
| Litigation settlements | **-** | 72 |
| Other | **(20)** | - |
| Corporate |  |  |
| Stock option expense | **(5,993)** | (5,166) |
| Excess tax benefits on stock compensation | **2,499** | 868 |
| Long-term incentive compensation | **(1,348)** | (1,543) |
| Total | **$(6,634)** | $(17,578) |

### Three months ended June 30, 2022 versus 2021 - Segment Results

Net income/(loss) for the second quarter of 2022 versus the second quarter of 2021 by segment (in thousands):

|  | Three months ended June 30, 2022 | 2021 |
| --- | ---: | ---: |
| VITAS | **35,212** | $29,712 |
| Roto-Rooter | **47,072** | 42,773 |
| Corporate | **(15,828)** | (15,963) |
|  | **$66,456** | $56,522 |

VITAS’ after-tax earnings increased primarily due to margin improvement and lower depreciation in the second quarter of 2022 when compared to the second quarter of 2021. After-tax earnings as a percent of revenue at VITAS in the second quarter of 2022 was 11.8% as compared to 9.5% in the second quarter of 2021.

Roto-Rooter’s net income was impacted in the second quarter of 2022 compared to the second quarter of 2021 primarily by higher revenue. After-tax earnings as a percent of revenue at Roto-Rooter in the second quarter of 2022 was 20.2%, as compared to 19.4% in the second quarter of 2021.

After-tax Corporate expenses for the second quarter of 2022 were essentially flat when compared to the second quarter of 2021.

### Results of Operations

### Six months ended June 30, 2022 versus 2021 - Consolidated Results

Our service revenues and sales for the first six months of 2022 increased 0.2% versus services and sales revenues for the first six months of 2021. Of this increase, a $33.0 million increase was attributable to Roto-Rooter offset by a $30.7 million decrease attributable to VITAS. The following chart shows the components of revenue by operating segment (in thousands):

| VITAS | Six months ended June 30, 2022 | 2021 | Increase/(Decrease) Percent |
| --- | ---: | ---: | ---: |
| Routine homecare | **$515,267** | $528,680 | (2.5) |
| Continuous care | **39,116** | 51,631 | (24.2) |
| General inpatient | **51,189** | 56,527 | (9.4) |
| Other | **6,220** | 6,016 | 3.4 |
| Subtotal | **611,792** | 642,854 | (4.8) |
| Medicare cap adjustment | **(4,500)** | (3,500) | (28.6) |
| Room and board - net | **(4,283)** | (5,322) | 19.5 |
| Implicit price concessions | **(6,039)** | (6,309) | 4.3 |
| Net revenue | **$596,970** | $627,723 | (4.9) |
| Roto-Rooter |  |  |  |
| Drain cleaning | **$131,219** | $124,406 | 5.5 |
| Plumbing | **96,557** | 85,922 | 12.4 |
| Excavation | **110,734** | 107,106 | 3.4 |
| Other | **321** | 598 | (46.3) |
| Subtotal - short term core | **338,831** | 318,032 | 6.5 |
| Water restoration | **84,033** | 76,018 | 10.5 |
| Independent Contractors | **42,423** | 37,785 | 12.3 |
| Outside franchisee fees | **2,688** | 2,582 | 4.1 |
| Other | **8,430** | 7,828 | 7.7 |
| Gross revenue | **476,405** | 442,245 | 7.7 |
| Implicit price concessions | **(11,538)** | (10,352) | (11.5) |
| Net revenue | **464,867** | $431,893 | 7.6 |
| Total Revenues | $1,061,837 | $1,059,616 | 0.2 |

Days of care at VITAS during the six months ended June 30 were as follows:

|  | Days of Care 2022 | 2021 | Increase/(Decrease) Percent |
| --- | ---: | ---: | ---: |
| Routine homecare | **2,525,276** | 2,665,374 | (5.3) |
| Nursing home | **507,514** | 477,206 | 6.4 |
| Respite | **11,463** | 10,178 | 12.6 |
| Subtotal routine homecare and respite | **3,044,253** | 3,152,758 | (3.4) |
| General inpatient | **47,742** | 54,167 | (11.9) |
| Continuous care | **41,884** | 55,086 | (24.0) |
| Total days of care | **3,133,879** | 3,262,011 | (3.9) |

The decrease in service revenues at VITAS is comprised primarily of a 3.9% decrease in days-of-care offset by a geographically weighted average Medicare reimbursement rate increase of approximately 1.0%. Acuity mix shift had a net impact of reducing revenue approximately 1.9% in the six months period when compared to the prior year revenue and level-of-care mix. The combination of an increase in Medicare cap and other contra revenue changes negatively impacted revenue growth by approximately 10 basis points.

The increase in plumbing revenues for the first six months of 2022 versus 2021 is attributable to a 13.1% increase in price and service mix shift and 0.7% decrease in job count. Drain cleaning revenues for the first six months of 2022 versus 2021 reflect an 11.3% increase in price and service mix shift offset by a 5.8% decrease in job count. Excavation and water restoration jobs are generally sold as a result of initial calls from customers regarding drain cleaning issues. As a result, the 3.4% increase in excavation revenue and the

10.5% increase in water restoration revenue are mainly a function of the numbers and size of drain cleaning issues we encounter on a quarterly basis. Independent Contractor revenue increased 12.3% due mainly to increased expansion into water restoration.

The consolidated gross margin was 36.6% in the first six months of 2022 as compared with 34.8% in the first six months of 2021. On a segment basis, VITAS’ gross margin was 23.8% in the first six months of 2022 as compared with 22.5%, in first six months of 2021 primarily a result of improved labor and ancillary costs. The Roto-Rooter segment’s gross margin was 53.0% for the first six months of 2022 as compared with 52.6% in the first six months of 2021 primarily due to increased revenue and improved labor costs.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

|  | Six months ended June 30, 2022 | 2021 |
| --- | ---: | ---: |
| SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts | **$184,000** | $175,178 |
| Impact of market value adjustments related to assets held in deferred compensation trusts | **(9,020)** | 6,693 |
| Long-term incentive compensation | **2,827** | 3,566 |
| Total SG&A expenses | **$177,807** | $185,437 |

SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts for the first six months of 2022 were up 5.0% when compared to the first six months of 2021. This increase was mainly a result of the increase in variable selling and general administrative expenses and due to normal salary increases.

Amortization for the first six months of 2022 was flat when compared to the first six months of 2021. Quarterly amortization of intangible assets is mainly driven by two Roto-Rooter franchise acquisitions completed in 2019. The total purchase price of these acquisitions was $138.0 million. As part of the purchase price allocation, approximately $59.2 million was determined to be the value of reacquired franchise rights which are being amortized over the remaining life of each franchise agreement. The average remaining life on the reacquired franchise agreements was approximately seven years. Quarterly amortization of reacquired franchise rights for these two acquisitions is approximately $2.0 million ($8.1 million annualized through 2026). This contrasts to quarterly franchise fees historically collected from these two franchisees of approximately $470,000 ($1.9 million annualized).

Other (expense)/income – net comprise (in thousands):

|  | Six months ended June 30, 2022 | 2021 |
| --- | ---: | ---: |
| Market value adjustment on assets held in deferred compensation trusts | **$(9,020)** | $6,693 |
| Interest income | **226** | 230 |
| Other | **2** | 464 |
| Total other (expense)/income - net | **$(8,792)** | $7,387 |

Our effective tax rate reconciliation is as follows (in thousands):

|  | Six months ended June 30, 2022 | 2021 |
| --- | ---: | ---: |
| Income tax provision calculated at the statutory federal rate | **$35,870** | $33,341 |
| Stock compensation tax benefits | **(3,940)** | (4,106) |
| State and local income taxes | **6,427** | 5,627 |
| Other--net | **1,826** | 1,983 |
| Income tax provision | **$40,183** | $36,845 |
| Effective tax rate | 23.5% | 23.2% |

Net income for both periods included the following after-tax items/adjustments that (reduced) or increased after-tax earnings (in thousands):

| VITAS | Six months ended June 30, 2022 | 2021 |
| --- | ---: | ---: |
| Direct costs related to COVID-19 | **$(231)** | $(9,576) |
| Medicare cap sequestration adjustment | **(103)** | - |
| Facility relocation costs | **-** | (1,384) |
| Roto-Rooter |  |  |
| Amortization of reacquired franchise agreements | **(3,457)** | (3,457) |
| Direct costs related to COVID-19 | **(707)** | (835) |
| Litigation settlements | **-** | 72 |
| Other | **(20)** | - |
| Corporate |  |  |
| Stock option expense | **(12,160)** | (10,232) |
| Excess tax benefits on stock compensation | **3,940** | 4,106 |
| Long-term incentive compensation | **(2,507)** | (3,212) |
| Direct costs related to COVID-19 | **-** | (30) |
| Total | **$(15,245)** | $(24,548) |

### Six months ended June 30, 2022 versus 2021 - Segment Results

Net income/(loss) for the first six months of 2022 versus the first six months of 2021 by segment (in thousands):

|  | Six months ended June 30, 2022 | 2021 |
| --- | ---: | ---: |
| VITAS | **$71,694** | $70,481 |
| Roto-Rooter | **91,009** | 79,950 |
| Corporate | **(32,078)** | (28,509) |
|  | **$130,625** | $121,922 |

VITAS’ after-tax earnings increased primarily due to lower revenue offset by improved margins and lower depreciation for the first six months of 2022 when compared to the first six months of 2021. After-tax earnings as a percent of revenue at VITAS in the first six months of 2022 was 12.0% as compared to 11.2% in the first six months of 2021.

Roto-Rooter’s net income was impacted in the first six months of 2022 compared to the first six months of 2021 primarily by higher revenue and improved labor costs. After-tax earnings as a percent of revenue at Roto-Rooter in the first six months of 2022 was 19.6%, as compared to 18.5% in the first six months of 2021.

After-tax Corporate expenses for the first six months of 2022 increased 12.5% when compared to the first six months of 2021 due to an $1.2 million increase in stock-based compensation expense, increase in interest expense, and a decrease in excess tax benefits on stock compensation.

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*CONSOLIDATING STATEMENTS OF INCOME*

*FOR THE THREE MONTHS ENDED JUNE 30, 2022*

*(in thousands)(unaudited)*

| 2022 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| **Service revenues and sales** | **$297,781** | **$233,507** | **$-** | **$531,288** |
| **Cost of services provided and goods sold** | **227,533** | **109,288** | **-** | **336,821** |
| **Selling, general and administrative expenses** | **23,148** | **54,982** | **9,723** | **87,853** |
| **Depreciation** | **6,062** | **6,634** | **18** | **12,714** |
| **Amortization** | **26** | **2,494** | **-** | **2,520** |
| **Other operating (income)/expense** | **(807)** | **249** | **-** | **(558)** |
| **Total costs and expenses** | **255,962** | **173,647** | **9,741** | **439,350** |
| **Income/(loss) from operations** | **41,819** | **59,860** | **(9,741)** | **91,938** |
| **Interest expense** | **(44)** | **(115)** | **(743)** | **(902)** |
| **Intercompany interest income/(expense)** | **4,683** | **2,205** | **(6,888)** | **-** |
| **Other income—net** | **119** | **37** | **(5,086)** | **(4,930)** |
| **Income/(expense) before income taxes** | **46,577** | **61,987** | **(22,458)** | **86,106** |
| **Income taxes** | **(11,365)** | **(14,915)** | **6,630** | **(19,650)** |
| **Net income/(loss)** | **$35,212** | **$47,072** | **$(15,828)** | **$66,456** |
| **(a) The following amounts are included in net income (in thousands):** |  |  |  |  |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| **Pretax benefit/(cost):** |  |  |  |  |
| **Stock option expense** | **$-** | **$-** | **$(7,216)** | **$(7,216)** |
| **Amortization of reacquired franchise agreements** | **-** | **(2,352)** | **-** | **(2,352)** |
| **Long-term incentive compensation** | **-** | **-** | **(1,517)** | **(1,517)** |
| **Medicare cap sequestration adjustment** | **(138)** | **-** | **-** | **(138)** |
| **Direct costs related to COVID-19** | **80** | **-** | **-** | **80** |
| **Other** | **-** | **(28)** | **-** | **(28)** |
| **Total** | **$(58)** | **$(2,380)** | **$(8,733)** | **$(11,171)** |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| **After-tax benefit/(cost):** |  |  |  |  |
| **Stock option expense** | **$-** | **$-** | **$(5,993)** | **$(5,993)** |
| **Amortization of reacquired franchise agreements** | **-** | **(1,729)** | **-** | **(1,729)** |
| **Long-term incentive compensation** | **-** | **-** | **(1,348)** | **(1,348)** |
| **Medicare cap sequestration adjustment** | **(103)** | **-** | **-** | **(103)** |
| **Direct costs related to COVID-19** | **60** | **-** | **-** | **60** |
| **Other** | **-** | **(20)** | **-** | **(20)** |
| **Excess tax benefits on stock compensation** | **-** | **-** | **2,499** | **2,499** |
| **Total** | **$(43)** | **$(1,749)** | **$(4,842)** | **$(6,634)** |

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*CONSOLIDATING STATEMENTS OF INCOME*

*FOR THE THREE MONTHS ENDED JUNE 30, 2021*

*(in thousands)(unaudited)*

| 2021 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| Service revenues and sales | $311,935 | $220,321 | $- | $532,256 |
| Cost of services provided and goods sold | 247,519 | 102,974 | - | 350,493 |
| Selling, general and administrative expenses | 22,631 | 53,556 | 17,651 | 93,838 |
| Depreciation | 7,125 | 6,468 | 19 | 13,612 |
| Amortization | 18 | 2,492 | - | 2,510 |
| Other operating expense | 87 | 17 | - | 104 |
| Total costs and expenses | 277,380 | 165,507 | 17,670 | 460,557 |
| Income/(loss) from operations | 34,555 | 54,814 | (17,670) | 71,699 |
| Interest expense | (43) | (89) | (247) | (379) |
| Intercompany interest income/(expense) | 4,486 | 1,649 | (6,135) | - |
| Other income—net | 99 | 32 | 3,654 | 3,785 |
| Income/(expense) before income taxes | 39,097 | 56,406 | (20,398) | 75,105 |
| Income taxes | (9,385) | (13,633) | 4,435 | (18,583) |
| Net income/(loss) | $29,712 | $42,773 | $(15,963) | $56,522 |
| (a) The following amounts are included in net income (in thousands): |  |  |  |  |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| Pretax benefit/(cost): |  |  |  |  |
| Direct costs related to COVID-19 | $(11,084) | $(582) | $- | $(11,666) |
| Stock option expense | - | - | (6,239) | (6,239) |
| Amortization of reacquired franchise agreements | - | (2,352) | - | (2,352) |
| Facility relocation costs | (1,855) |  |  | (1,855) |
| Long-term incentive compensation | - | - | (1,673) | (1,673) |
| Litigation settlements |  | 98 |  | 98 |
| Total | $(12,939) | $(2,836) | $(7,912) | $(23,687) |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| After-tax benefit/(cost): |  |  |  |  |
| Direct costs related to COVID-19 | $(8,268) | $(428) | $- | $(8,696) |
| Stock option expense | - | - | (5,166) | (5,166) |
| Amortization of reacquired franchise agreements | - | (1,729) | - | (1,729) |
| Long-term incentive compensation | - | - | (1,543) | (1,543) |
| Facility relocation costs | (1,384) |  |  | (1,384) |
| Litigation settlements |  | 72 |  | 72 |
| Excess tax benefits on stock compensation | - | - | 868 | 868 |
| Total | $(9,652) | $(2,085) | $(5,841) | $(17,578) |

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*CONSOLIDATING STATEMENTS OF INCOME*

*FOR THE SIX MONTHS ENDED JUNE 30, 2022*

*(in thousands)(unaudited)*

| 2022 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| **Service revenues and sales** | **$596,970** | **$464,867** | **$-** | **$1,061,837** |
| **Cost of services provided and goods sold** | **454,773** | **218,600** | **-** | **673,373** |
| **Selling, general and administrative expenses** | **45,600** | **111,937** | **20,270** | **177,807** |
| **Depreciation** | **11,613** | **13,203** | **36** | **24,852** |
| **Amortization** | **49** | **4,989** | **-** | **5,038** |
| **Other operating (income)/expense** | **(955)** | **410** | **-** | **(545)** |
| **Total costs and expenses** | **511,080** | **349,139** | **20,306** | **880,525** |
| **Income/(loss) from operations** | **85,890** | **115,728** | **(20,306)** | **181,312** |
| **Interest expense** | **(96)** | **(229)** | **(1,387)** | **(1,712)** |
| **Intercompany interest income/(expense)** | **9,339** | **4,381** | **(13,720)** | **-** |
| **Other income—net** | **156** | **72** | **(9,020)** | **(8,792)** |
| **Income/(expense) before income taxes** | **95,289** | **119,952** | **(44,433)** | **170,808** |
| **Income taxes** | **(23,595)** | **(28,943)** | **12,355** | **(40,183)** |
| **Net income/(loss)** | **$71,694** | **$91,009** | **$(32,078)** | **$130,625** |
| **(a) The following amounts are included in net income (in thousands):** |  |  |  |  |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| **Pretax benefit/(cost):** |  |  |  |  |
| **Stock option expense** | **$-** | **$-** | **$(14,667)** | **$(14,667)** |
| **Amortization of reacquired franchise agreements** | **-** | **(4,704)** | **-** | **(4,704)** |
| **Long-term incentive compensation** | **-** | **-** | **(2,827)** | **(2,827)** |
| **Direct costs related to COVID-19** | **(310)** | **(960)** | **-** | **(1,270)** |
| **Medicare cap sequestration adjustment** | **(138)** | **-** | **-** | **(138)** |
| **Other** | **-** | **(28)** | **-** | **(28)** |
| **Total** | **$(448)** | **$(5,692)** | **$(17,494)** | **$(23,634)** |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| **After-tax benefit/(cost):** |  |  |  |  |
| **Stock option expense** | **$-** | **$-** | **$(12,160)** | **$(12,160)** |
| **Amortization of reacquired franchise agreements** | **-** | **(3,457)** | **-** | **(3,457)** |
| **Long-term incentive compensation** | **-** | **-** | **(2,507)** | **(2,507)** |
| **Direct costs related to COVID-19** | **(231)** | **(707)** | **-** | **(938)** |
| **Medicare cap sequestration adjustment** | **(103)** | **-** | **-** | **(103)** |
| **Other** | **-** | **(20)** |  | **(20)** |
| **Excess tax benefits on stock compensation** | **-** | **-** | **3,940** | **3,940** |
| **Total** | **$(334)** | **$(4,184)** | **$(10,727)** | **$(15,245)** |

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*CONSOLIDATING STATEMENTS OF INCOME*

*FOR THE SIX MONTHS ENDED JUNE 30, 2021*

*(in thousands)(unaudited)*

| 2021 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| Service revenues and sales | $627,723 | $431,893 | $- | $1,059,616 |
| Cost of services provided and goods sold | 486,186 | 204,780 | - | 690,966 |
| Selling, general and administrative expenses | 44,721 | 106,878 | 33,838 | 185,437 |
| Depreciation | 12,462 | 12,821 | 44 | 25,327 |
| Amortization | 36 | 4,984 | - | 5,020 |
| Other operating expense | 590 | 136 | - | 726 |
| Total costs and expenses | 543,995 | 329,599 | 33,882 | 907,476 |
| Income/(loss) from operations | 83,728 | 102,294 | (33,882) | 152,140 |
| Interest expense | (85) | (179) | (496) | (760) |
| Intercompany interest income/(expense) | 9,011 | 3,269 | (12,280) | - |
| Other income—net | 632 | 63 | 6,692 | 7,387 |
| Income/(expense) before income taxes | 93,286 | 105,447 | (39,966) | 158,767 |
| Income taxes | (22,805) | (25,497) | 11,457 | (36,845) |
| Net income/(loss) | $70,481 | $79,950 | $(28,509) | $121,922 |
| (a) The following amounts are included in net income (in thousands): |  |  |  |  |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| Pretax benefit/(cost): |  |  |  |  |
| Direct costs related to COVID-19 | $(12,836) | $(1,136) | $(38) | $(14,010) |
| Stock option expense | - | - | (12,345) | (12,345) |
| Amortization of reacquired franchise agreements | - | (4,704) | - | (4,704) |
| Long-term incentive compensation | - | - | (3,566) | (3,566) |
| Facility relocation costs | (1,855) | - | - | (1,855) |
| Litigation settlements | - | 98 | - | 98 |
| Total | $(14,691) | $(5,742) | $(15,949) | $(36,382) |
|  |  |  |  | **Chemed** |
|  | **VITAS** | **Roto-Rooter** | **Corporate** | **Consolidated** |
| After-tax benefit/(cost): |  |  |  |  |
| Direct costs related to COVID-19 | $(9,576) | $(835) | $(30) | $(10,441) |
| Stock option expense | - | - | (10,232) | (10,232) |
| Amortization of reacquired franchise agreements | - | (3,457) | - | (3,457) |
| Long-term incentive compensation | - | - | (3,212) | (3,212) |
| Facility relocation costs | (1,384) |  |  | (1,384) |
| Litigation settlements |  | 72 |  | 72 |
| Excess tax benefits on stock compensation | - | - | 4,106 | 4,106 |
| Total | $(10,960) | $(4,220) | $(9,368) | $(24,548) |

*Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA*

*(in thousands)*

| Chemed Corporation and Subsidiary Companies For the three months ended June 30, 2022 | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| **Net income/(loss)** | $35,212 | **$47,072** | **$(15,828)** | **$66,456** |
| **Add/(deduct):** |  |  |  |  |
| **Interest expense** | **44** | **115** | **743** | **902** |
| **Income taxes** | **11,365** | **14,915** | **(6,630)** | **19,650** |
| **Depreciation** | **6,062** | **6,634** | **18** | **12,714** |
| **Amortization** | **26** | **2,494** | **-** | **2,520** |
| **EBITDA** | **52,709** | **71,230** | **(21,697)** | **102,242** |
| **Add/(deduct):** |  |  |  |  |
| **Intercompany interest expense/(income)** | **(4,683)** | **(2,205)** | **6,888** | **-** |
| **Interest income** | **(118)** | **(37)** | **1** | **(154)** |
| **Stock option expense** | **-** | **-** | **7,216** | **7,216** |
| **Long-term incentive compensation** | **-** | **-** | **1,517** | **1,517** |
| **Medicare cap sequestration adjustment** | **138** | **-** | **-** | **138** |
| **Direct costs related to COVID-19** | **(80)** | **-** | **-** | **(80)** |
| **Other** | **-** | **28** | **-** | **28** |
| **Adjusted EBITDA** | **$47,966** | **$69,016** | **$(6,075)** | **$110,907** |
|  |  |  |  | Chemed |
| For the three months ended June 30, 2021 | VITAS | Roto-Rooter | Corporate | Consolidated |
| Net income/(loss) | $29,712 | $42,773 | $(15,963) | $56,522 |
| Add/(deduct): |  |  |  |  |
| Interest expense | 43 | 89 | 247 | 379 |
| Income taxes | 9,385 | 13,633 | (4,435) | 18,583 |
| Depreciation | 7,125 | 6,468 | 19 | 13,612 |
| Amortization | 18 | 2,492 | - | 2,510 |
| EBITDA | 46,283 | 65,455 | (20,132) | 91,606 |
| Add/(deduct): |  |  |  |  |
| Intercompany interest expense/(income) | (4,486) | (1,649) | 6,135 | - |
| Interest income | (106) | (32) | - | (138) |
| Direct costs related to COVID-19 | 11,084 | 582 | - | 11,666 |
| Stock option expense | - | - | 6,239 | 6,239 |
| Long-term incentive compensation | - | - | 1,673 | 1,673 |
| Litigation settlement | - | (98) | - | (98) |
| Adjusted EBITDA | $52,775 | $64,258 | $(6,085) | $110,948 |

*Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA*

*(in thousands)*

| Chemed Corporation and Subsidiary Companies For the six months ended June 30, 2022 | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| **Net income/(loss)** | $71,694 | **$91,009** | **$(32,078)** | **$130,625** |
| **Add/(deduct):** |  |  |  |  |
| **Interest expense** | **96** | **229** | **1,387** | **1,712** |
| **Income taxes** | **23,595** | **28,943** | **(12,355)** | **40,183** |
| **Depreciation** | **11,613** | **13,203** | **36** | **24,852** |
| **Amortization** | **49** | **4,989** | **-** | **5,038** |
| **EBITDA** | **107,047** | **138,373** | **(43,010)** | **202,410** |
| **Add/(deduct):** |  |  |  |  |
| **Intercompany interest expense/(income)** | **(9,339)** | **(4,381)** | **13,720** | **-** |
| **Interest income** | **(155)** | **(71)** | **-** | **(226)** |
| **Stock option expense** | **-** | **-** | **14,667** | **14,667** |
| **Long-term incentive compensation** | **-** | **-** | **2,827** | **2,827** |
| **Direct costs related to COVID-19** | **310** | **960** | **-** | **1,270** |
| **Medicare cap sequestration adjustment** | **138** | **-** | **-** | **138** |
| **Other** | **-** | **28** | **-** | **28** |
| **Adjusted EBITDA** | **$98,001** | **$134,909** | **$(11,796)** | **$221,114** |
|  |  |  |  | Chemed |
| For the six months ended June 30, 2021 | VITAS | Roto-Rooter | Corporate | Consolidated |
| Net income/(loss) | $70,481 | $79,950 | $(28,509) | $121,922 |
| Add/(deduct): |  |  |  |  |
| Interest expense | 85 | 179 | 496 | 760 |
| Income taxes | 22,805 | 25,497 | (11,457) | 36,845 |
| Depreciation | 12,462 | 12,821 | 44 | 25,327 |
| Amortization | 36 | 4,984 | - | 5,020 |
| EBITDA | 105,869 | 123,431 | (39,426) | 189,874 |
| Add/(deduct): |  |  |  |  |
| Intercompany interest expense/(income) | (9,011) | (3,269) | 12,280 | - |
| Interest income | (167) | (63) | - | (230) |
| Direct costs related to COVID-19 | 12,836 | 1,136 | 38 | 14,010 |
| Stock option expense | - | - | 12,345 | 12,345 |
| Long-term incentive compensation | - | - | 3,566 | 3,566 |
| Litigation settlement | - | (98) |  | (98) |
| Adjusted EBITDA | $109,527 | $121,137 | $(11,197) | $219,467 |

*RECONCILIATION OF ADJUSTED NET INCOME*

*(in thousands, except per share data)(unaudited)*

|  | Three Months Ended June 30, 2022 | 2021 | Six Months Ended June 30, 2022 | 2021 |
| --- | ---: | ---: | ---: | ---: |
| Net income as reported | **$66,456** | $56,522 | **$130,625** | $121,922 |
| Add/(deduct) pre-tax cost of: |  |  |  |  |
| Stock option expense | **7,216** | 6,239 | **14,667** | 12,345 |
| Amortization of reacquired franchise agreements | **2,352** | 2,352 | **4,704** | 4,704 |
| Long-term incentive compensation | **1,517** | 1,673 | **2,827** | 3,566 |
| Direct costs related to COVID-19 | **(80)** | 11,666 | **1,270** | 14,010 |
| Medicare cap sequestration adjustment | **138** | - | **138** | - |
| Other | **28** | - | **28** | - |
| Facility relocation cost | **-** | 1,855 | **-** | 1,855 |
| Litigation settlements | **-** | (98) | **-** | (98) |
| Add/(deduct) tax impacts: |  |  |  |  |
| Tax impact of the above pre-tax adjustments (1) | **(2,038)** | (5,241) | **(4,449)** | (7,728) |
| Excess tax benefits on stock compensation | **(2,499)** | (868) | **(3,940)** | (4,106) |
| Adjusted net income | **$73,090** | $74,100 | **$145,870** | $146,470 |
| Diluted Earnings Per Share As Reported |  |  |  |  |
| Net income | **$4.40** | $3.51 | **$8.62** | $7.52 |
| Average number of shares outstanding | **15,111** | 16,101 | **15,152** | 16,205 |
| Adjusted Diluted Earnings Per Share |  |  |  |  |
| Adjusted net income | **$4.84** | $4.60 | **$9.63** | $9.04 |
| Adjusted average number of shares outstanding | **15,111** | 16,101 | **15,152** | 16,205 |
| (1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated. |  |  |  |  |

*CHEMED CORPORATION AND SUBSIDIARY COMPANIES*

*OPERATING STATISTICS FOR VITAS SEGMENT*

*(unaudited)*

| OPERATING STATISTICS Net revenue ($000) | Three Months Ended June 30, 2022 | 2021 | Six Months Ended June 30, 2022 | 2021 |
| --- | ---: | ---: | ---: | ---: |
| Homecare | **$257,631** | $264,926 | **$515,267** | $528,680 |
| Inpatient | **24,619** | 27,371 | **51,189** | 56,527 |
| Continuous care | **19,538** | 24,282 | **39,116** | 51,631 |
| Other | **3,213** | 3,078 | **6,220** | 6,016 |
| Subtotal | **$305,001** | $319,657 | **$611,792** | $642,854 |
| Room and board, net | **(2,166)** | (2,657) | **(4,283)** | (5,322) |
| Contractual allowances | **(3,054)** | (3,065) | **(6,039)** | (6,309) |
| Medicare cap allowance | **(2,000)** | (2,000) | **(4,500)** | (3,500) |
| Total | **$297,781** | $311,935 | **$596,970** | $627,723 |
| Net revenue as a percent of total before Medicare cap allowances |  |  |  |  |
| Homecare | **84.5%** | 82.9% | **84.2%** | 82.2% |
| Inpatient | **8.1** | 8.6 | **8.4** | 8.8 |
| Continuous care | **6.4** | 7.6 | **6.4** | 8.0 |
| Other | **1.0** | 0.9 | **1.0** | 1.0 |
| Subtotal | **100.0** | 100.0 | **100.0** | 100.0 |
| Room and board, net | **(0.7)** | (0.8) | **(0.7)** | (0.8) |
| Contractual allowances | **(1.0)** | (1.0) | **(1.0)** | (1.0) |
| Medicare cap allowance | **(0.7)** | (0.6) | **(0.7)** | (0.6) |
| Total | **97.6%** | 97.6% | **97.6%** | 97.6% |
| Days of care |  |  |  |  |
| Homecare | **1,266,604** | 1,335,482 | **2,525,276** | 2,665,374 |
| Nursing home | **259,046** | 244,423 | **507,514** | 477,206 |
| Respite | **6,095** | 5,338 | **11,463** | 10,178 |
| Subtotal routine homecare and respite | **1,531,745** | 1,585,243 | **3,044,253** | 3,152,758 |
| Inpatient | **23,155** | 26,493 | **47,742** | 54,167 |
| Continuous care | **20,802** | 25,786 | **41,884** | 55,086 |
| Total | **1,575,702** | 1,637,522 | **3,133,879** | 3,262,011 |
| Number of days in relevant time period | **91** | 91 | **181** | 181 |
| Average daily census (days) |  |  |  |  |
| Homecare | **13,918** | 14,676 | **13,952** | 14,726 |
| Nursing home | **2,847** | 2,686 | **2,804** | 2,636 |
| Respite | **67** | 59 | **63** | 57 |
| Subtotal routine homecare and respite | **16,832** | 17,421 | **16,819** | 17,419 |
| Inpatient | **254** | 291 | **264** | 299 |
| Continuous care | **229** | 283 | **231** | 304 |
| Total | **17,315** | 17,995 | **17,314** | 18,022 |
| Total Admissions | **14,735** | 16,840 | **31,265** | 34,975 |
| Total Discharges | **14,603** | 16,525 | **31,465** | 35,054 |
| Average length of stay (days) | **103.7** | 94.5 | **104.3** | 94.4 |
| Median length of stay (days) | **17.0** | 14.0 | **16.0** | 13.0 |
| ADC by major diagnosis |  |  |  |  |
| Cerebro | **37.6%** | 36.8% | **37.5%** | 36.5% |
| Neurological | **22.7** | 22.4 | **22.8** | 22.3 |
| Cancer | **11.2** | 12.1 | **11.2** | 12.2 |
| Cardio | **15.8** | 15.6 | **15.8** | 15.6 |
| Respiratory | **7.2** | 7.3 | **7.3** | 7.5 |
| Other | **5.5** | 5.8 | **5.4** | 5.9 |
| Total | **100.0%** | 100.0% | **100.0%** | 100.0% |
| Admissions by major diagnosis |  |  |  |  |
| Cerebro | **23.8** | 21.4% | **23.4%** | 21.5% |
| Neurological | **13.0** | 12.3 | **12.9** | 12.3 |
| Cancer | **27.3** | 28.9 | **26.0** | 26.9 |
| Cardio | **15.4** | 14.8 | **14.7** | 14.5 |
| Respiratory | **9.9** | 10.5 | **10.6** | 10.7 |
| Other | **10.6** | 12.1 | **12.4** | 14.1 |
| Total | **100.0%** | 100.0% | **100.0%** | 100.0% |
| Estimated uncollectible accounts as a percent of revenues | **1.0%** | 1.0% | **1.0%** | 1.0% |
| Accounts receivable -- |  |  |  |  |
| Days of revenue outstanding- excluding unapplied Medicare payments | **33.7** | 36.3 | **n.a.** | n.a. |
| Days of revenue outstanding- including unapplied Medicare payments | **28.2** | 21.0 | **n.a.** | n.a. |

### Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information

Certain statements contained in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “hope”, “anticipate”, “plan” and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. These forward-looking statements are based on current expectations and assumptions and involve various known and unknown risks, uncertainties, contingencies and other factors, which could cause Chemed’s actual results to differ from those expressed in such forward-looking statements. Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends. In addition, our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of projections and other financial matters. Investors are cautioned that such forward-looking statements are subject to inherent risk and there are no assurances that the matters contained in such statements will be achieved. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of a new information, future events or otherwise.

## Market risk

As filed, 586 characters.

The Company’s primary market risk exposure relates to interest rate risk exposure through its variable interest line of credit. At June 30, 2022, the Company had $116.8 million of variable rate debt outstanding. For each $10 million borrowed under the credit facility, an increase or decrease of 100 basis points (1%), increases or decreases the Company’s annual interest expense by $100,000.

The Company continually evaluates this interest rate exposure and periodically weighs the cost versus the benefit of fixing the variable interest rates through a variety of hedging techniques.

## Controls and procedures

As filed, 900 characters.

We carried out an evaluation, under the supervision of our President and Chief Executive Officer and with the participation of the Executive Vice President and Chief Financial Officer and the Vice President and Controller, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the President and Chief Executive Officer, Executive Vice President and Chief Financial Officer and Vice President and Controller have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. There has been no change in our internal control over financial reporting that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 141 characters.

There have been no other material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.

Filed Jul 29, 2022.
Source: SEC EDGAR, the filing index for accession 0001562762-22-000308. Last ingested by Listed: Nov 14, 2026, 12:29 ET. No prices; not investment advice.
